背景:疟疾仍然是整个非洲巨大的公共卫生障碍,东南亚,和南美洲的部分地区,对抗疟药物的耐药性加剧了,如青蒿素类组合。姜黄素和青蒿素的组合由于其减少剂量的潜力而显示出希望,降低毒性,协同效应,以及改善药物输送的适用性。
目的:本研究旨在通过使用固体脂质纳米粒(SLN)来提高姜黄素和青蒿素的溶解度和溶出速率。这两种药物的口服给药都面临着挑战,因为它们的水溶性差。低效吸收,和快速的新陈代谢和消除。
方法:该研究的重点是配制和优化包封青蒿素(ART)和姜黄素(CUR)的固体脂质纳米颗粒(SLN)。SLN是使用热均化法开发的,结合超声处理。使用差示扫描量热法(DSC)评价药物-赋形剂相容性。进行脂质和表面活性剂筛选以选择合适的组分。3²全因子设计用于研究脂质和表面活性剂浓度对关键参数的影响,如包封效率(%EE)和累积药物释放(%CDR)。此外,%截留效率的评估,药物装载,颗粒大小,zeta电位,并进行了体外药物释放。
结果:青蒿素和姜黄素SLN的成功开发是通过全因子设计实现的,显示受控的药物释放和高包封效率。优化后的纳米粒子尺寸为114.7nm,均匀性(PDI:0.261),和-9.24mV的ζ电位。青蒿素和姜黄素的%EE值分别为79.1%和74.5%,分别,累积药物释放量分别为85.1%和80.9%,分别。全因子设计表明,增加的脂质浓度提高了%EE,而较高的表面活性剂浓度增强了药物释放和%EE。优化批次的稳定性研究显示物理或化学特性没有变化。
结论:该研究成功开发了青蒿素和姜黄素的固体脂质纳米粒(SLN),实现药物控制释放,高包封效率,和所需的粒度和均匀性。这一进步有望增强草药制剂的药物递送。
BACKGROUND: Malaria remains a formidable public health obstacle across Africa, Southeast Asia, and portions of South America, exacerbated by resistance to antimalarial medications, such as artemisinin-based combinations. The combination of curcumin and artemisinin shows promise due to its potential for dose reduction, reduced toxicity, synergistic effects, and suitability for drug delivery improvement.
OBJECTIVE: This research aims to enhance the solubility and dissolution rates of curcumin and artemisinin by employing Solid Lipid Nanoparticles (SLNs). Oral delivery of both drugs faces challenges due to their poor water solubility, inefficient absorption, and rapid metabolism and elimination.
METHODS: The study focuses on formulating and optimizing Solid Lipid Nanoparticles (SLNs) encapsulating artemisinin (ART) and curcumin (CUR). SLNs were developed using the hot homogenization method, incorporating ultrasonication. Drug-excipient compatibility was evaluated using Differential Scanning Calorimetry (DSC). Lipid and surfactant screening was performed to select suitable components. A 3² full factorial design was utilized to investigate the influence of lipid and surfactant concentrations on key parameters, such as entrapment efficiency (%EE) and cumulative drug release (%CDR). Additionally, evaluations of % entrapment efficiency, drug loading, particle size, zeta potential, and in-vitro drug release were conducted.
RESULTS: Successful development of artemisinin and curcumin SLNs was achieved using a full factorial design, demonstrating controlled drug release and high entrapment efficiency. The optimized nanoparticles exhibited a size of 114.7nm, uniformity (PDI: 0.261), and a zeta potential of -9.24 mV. Artemisinin and curcumin showed %EE values of 79.1% and 74.5%, respectively, with cumulative drug release of 85.1% and 80.9%, respectively. The full factorial design indicated that increased lipid concentration improved %EE, while higher surfactant concentration enhanced drug release and %EE. Stability studies of the optimized batch revealed no alterations in physical or chemical characteristics.
CONCLUSIONS: The study successfully developed Solid Lipid Nanoparticles (SLNs) for artemisinin and curcumin, achieving controlled drug release, high entrapment efficiency, and desired particle size and uniformity. This advancement holds promise for enhancing drug delivery of herbal formulations.